Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP3 | P08254 | 6/20 | 0.35 |
| ▸ | MMP1 | P03956 | 5/20 | 0.35 |
| ▸ | MMP2 | P08253 | 5/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | REN | P00797 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | KIF11 | P52732 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1449763 | 0.87 | TP53 (0.38) | MMP3MMP1MMP2TP53CYP1A2 | |
| SCHEMBL1450242 | 0.87 | MMP1 (0.39) | MMP3MMP1MMP2RENRAB9A | |
| SCHEMBL1449640 | 0.86 | TP53 (0.33) | MMP3MMP1MMP2TP53CYP1A2 | |
| SCHEMBL1449333 | 0.85 | MMP1 (0.39) | MMP3MMP1MMP2TDP1REN | |
| SCHEMBL1449086 | 0.83 | SLC6A2 (0.41) | MMP3MMP1MMP2RENRAB9A | |
| SCHEMBL265370 | 0.83 | MMP1 (0.39) | MMP3MMP1MMP2TP53CYP1A2 | |
| SCHEMBL1449414 | 0.83 | POLB (0.36) | MMP3MMP1MMP2TP53CYP1A2 | |
| SCHEMBL1449348 | 0.83 | MMP3 (0.39) | MMP3MMP1MMP2TSHRREN | |
| Hydrochloric Acid SCHEMBL266228 | 0.82 | MMP1 (0.38) | MMP3MMP1MMP2TP53CYP1A2 | |
| SCHEMBL1449467 | 0.82 | CIT (0.33) | MMP3MMP1MMP2TP53CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7910556-B2 | PAR-2 agonist | KOWA COMPANY, LTD. (JP) | 2011-03-22 | — | — | US | claimed |
| US-20090131330-A1 | PAR-2 AGONIST | KOWA CO., LTD. (JP) | 2009-05-21 | — | — | US | claimed |
| EP-1845104-A1 | PAR-2 AGONIST | Kowa Company. Ltd. (JP) | 2007-10-17 | — | — | EP | claimed |
| US-7910556-B2 | PAR-2 agonist | KOWA COMPANY, LTD. (JP) | 2011-03-22 | — | — | US | disclosed |
| US-20090131330-A1 | PAR-2 AGONIST | KOWA CO., LTD. (JP) | 2009-05-21 | — | — | US | disclosed |
| EP-1845104-A1 | PAR-2 AGONIST | Kowa Company. Ltd. (JP) | 2007-10-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131330-A1 | PAR-2 AGONIST | F2RL1, CNR2, FFAR2 | MMP3 1292/4885MMP1 3129/4885MMP2 2853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.